Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis.

MLA

Luangmonkong, Theerut, et al. “Evaluating the Antifibrotic Potency of Galunisertib in a Human Ex Vivo Model of Liver Fibrosis.” British Journal of Pharmacology, vol. 174, no. 18, Sept. 2017, pp. 3107–17. EBSCOhost, https://doi.org/10.1111/bph.13945.

APA

Luangmonkong, T., Suriguga, S., Bigaeva, E., Boersema, M., Oosterhuis, D., de Jong, K. P., Schuppan, D., Mutsaers, H. A. M., & Olinga, P. (2017). Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis. British Journal of Pharmacology, 174(18), 3107–3117. https://doi.org/10.1111/bph.13945

Chicago

Luangmonkong, Theerut, Su Suriguga, Emilia Bigaeva, Miriam Boersema, Dorenda Oosterhuis, Koert P de Jong, Detlef Schuppan, Henricus A M Mutsaers, and Peter Olinga. 2017. “Evaluating the Antifibrotic Potency of Galunisertib in a Human Ex Vivo Model of Liver Fibrosis.” British Journal of Pharmacology 174 (18): 3107–17. doi:10.1111/bph.13945.